According to Swedish Orphan Biovitrum's latest financial reports the company has NZ$0.17 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-12-31 | NZ$0.18 B | 29.18% |
2023-12-31 | NZ$0.14 B | -31.15% |
2022-12-31 | NZ$0.20 B | 21.9% |
2021-12-31 | NZ$0.16 B | 147.33% |
2020-12-31 | NZ$68.37 M | -41.61% |
2019-12-31 | NZ$0.11 B | -76.48% |
2018-12-31 | NZ$0.49 B | 95.63% |
2017-12-31 | NZ$0.25 B | 103.75% |
2016-12-31 | NZ$0.12 B | -20.44% |
2015-12-31 | NZ$0.15 B | 83.7% |
2014-12-31 | NZ$85.46 M | 1.16% |
2013-12-31 | NZ$84.48 M | -1.12% |
2012-12-31 | NZ$85.43 M | 109.33% |
2011-12-31 | NZ$40.81 M | 452.31% |
2010-12-31 | NZ$7.38 M | -87.61% |
2009-12-31 | NZ$59.64 M | -41.09% |
2008-12-31 | NZ$0.10 B | -34.12% |
2007-12-31 | NZ$0.15 B | -18.04% |
2006-12-31 | NZ$0.18 B | -3.62% |
2005-12-31 | NZ$0.19 B | -12.04% |
2004-12-31 | NZ$0.22 B | 756.51% |
2003-12-31 | NZ$25.82 M | 11.28% |
2002-12-31 | NZ$23.2 M |